세계 흑색종 치료제 시장 규모는 2023년 74억 달러에서 예측 기간 동안 10.2%의 CAGR을 기록하며 2028년 121억 달러 규모로 성장할 것으로 예상됩니다.
지역별로 살펴보면, 북미 시장은 2023년 35억 달러에서 2028년 58억 달러 규모로 성장해 연평균 11.0%의 성장률을 기록할 것으로 예상됩니다. 유럽 시장은 2023년 23억 달러에서 연평균 10.1% 성장해 2028년 38억 달러 규모로 성장할 것으로 예상됩니다.
세계 흑색종 치료제 시장을 조사했으며, 시장 및 기술 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별·지역별 상세 분석, 기술 및 특허 동향, 파이프라인 분석, ESG 전개, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 서론
제2장 요약과 하이라이트
시장 전망
시장 요약
제3장 시장 및 기술 배경
위험인자·원인·예방
증상
병태생리·임상 아류형
예후
역학
진단
생검
임상 검사
혈액 검사
영상 검사
치료
면역요법
PD-1 및 PD-L1 억제제
CTLA-4 억제제
LAG-3 억제제
인터류킨-2(IL-2, 프로류킨)
바이러스 요법
BRAF 억제제
MEK 억제제
제4장 시장 역학
시장 요인
시장 성장 촉진요인
흑색종 유병률 증가
기술 진보와 제품 발매
전략적 대처
조기 발견 툴의 개발
환자 옹호 단체와 의식 향상
시장 성장 억제요인
고액의 치료비
엄격한 규제
치료에 대한 내성
시장 기회
제5장 시장 내역 : 유형별
개요
수술
광범위 절제
모스 수술
절단
림프절 절제술
치료법
치료법 : 유형별
방사선 치료
제6장 시장 내역 : 질환 스테이지별
개요
국한성 질환
국소성 질환
원격 질환
제7장 시장 내역 : 지역별
개요
북미
유럽
아시아태평양
기타 지역
제8장 지속가능성 : ESG 관점
제약 업계의 ESG 과제
흑색종 치료제 시장의 ESG 관행
환경에 대한 대처
사회에 대한 대처
거버넌스에 대한 대처
사례 연구
BCC에 의한 견해
제9장 신기술/개발
신규 면역관문억제제
양자 세포 치료
Engineered TCR 요법
백신
표적요법
제10장 규제 상황·파이프라인 분석
규제 상황
미국
유럽
일본
파이프라인 분석
제11장 특허 분석
제12장 경쟁 상황
M&A
전략적 대처
경쟁 분석
제13장 기업 개요
AMGEN INC.
ASTRAZENECA PLC
BRISTOL-MYERS SQUIBB
ERASCA INC.
F. HOFFMANN-LA ROCHE AG
HUYABIO INTERNATIONAL
IOVANCE BIOTHERAPEUTICS INC.
IO BIOTECH
MERCK & CO. INC.
MODERNA INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
ksm
영문 목차
영문목차
Highlights:
The global market for melanoma therapeutics is estimated to increase from $7.4 billion in 2023 to reach $12.1 billion by 2028, at a compound annual growth rate (CAGR) of 10.2% from 2023 through 2028.
North American market for melanoma therapeutics is estimated to increase from $3.5 billion in 2023 to reach $5.8 billion by 2028, at a compound annual growth rate (CAGR) of 11.0% from 2023 through 2028.
European market for melanoma therapeutics is estimated to increase from $2.3 billion in 2023 to reach $3.8 billion by 2028, at a compound annual growth rate (CAGR) of 10.1% from 2023 through 2028.
Report Scope:
This study investigates the melanoma treatment market. BCC Research analyzes melanoma treatment based on treatment type, cancer stage and type of therapeutics. BCC determines the current market status in each segment, examines its impact on future needs and presents growth forecasts over the next five years. The report provides a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections through 2028 and analyzes market share for key market players. In its profiles of key companies, the report provides detailed information about their business segments, financials, product portfolios and recent developments. The report also discusses the market impact of the COVID-19 pandemic, emerging technologies, and new developments, ESG development and investment outlook.
Report Includes:
30 data tables and 18 additional tables
An overview of the global market for melanoma treatment
Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Description of various treatment options such as chemotherapy, surgical resection, immunotherapy, and targeted therapies; and various treatment approaches for the betterment of patient's overall health
A look at the advancements in the genetic profiling of melanocytes and identification of novel molecules that involved in melanoma's development
Information on new potential therapeutic target discovery; and description of novel immune checkpoint inhibitors, adoptive cell therapy and engineered TCR therapy
Coverage of innovation, technological advancements, and the launch of novel products from market players
Detailed analysis of the regulatory framework and policies and product pipeline of the industry, and discussion on ESG challenges in the pharmaceutical industry and ESG practices in the melanoma treatment market
Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
Comprehensive company profiles of the leading players of the industry, including Amgen, Roche, Merck & Co., Pfizer Inc., BMS, and Novartis AG
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Scope of the Report
Reasons for Doing the Study
Methodology
Information Sources
Geographic Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Market Summary
Chapter 3 Market and Technology Background
Introduction
Risk Factors, Causes and Prevention
Symptoms
Pathophysiology and Clinical Subtypes
Prognosis
Epidemiology
Diagnosis
Biopsy
Laboratory Tests
Blood Tests
Imaging Tests
Treatment
Immunotherapy
PD-1 and PD-L1 Inhibitors
CTLA-4 inhibitors
LAG-3 Inhibitors
Interleukin-2 (IL-2, Proleukin)
Virus Therapy
BRAF inhibitors:
MEK Inhibitors
Chapter 4 Market Dynamics
Market Factors
Market Drivers
Increasing Prevalence of Melanoma
Technological Advancements and Product Launches
Strategic Initiatives
Developments in Early Detection Tools
Patient Advocacy Groups and Awareness
Market Restraints
High Cost of Treatment
Stringent Regulations
Resistance to Therapies
Market Opportunities
Chapter 5 Market Breakdown by Type
Overview
Surgery
Wide Excision
Mohs Surgery
Amputation
Lymph Node Dissection
Therapeutics
Therapeutics by Type
Radiation Therapy
Chapter 6 Market Breakdown by Disease Stage
Overview
Localized Disease
Regional Disease
Distant Disease
Chapter 7 Market Breakdown by Region
Overview
North America
Europe
Asia-Pacific
Rest of the World
Chapter 8 Sustainability: An ESG Perspective
Introduction
ESG Challenges in the Pharmaceutical Industry
ESG Practices in the Market for Melanoma Therapeutics
Environmental Initiatives
Social Initiatives
Governance Initiatives
Case Study
BCC Research Viewpoint
Chapter 9 Emerging Technologies/ Developments
Introduction
Novel Immune Checkpoint Inhibitors
Adoptive Cell Therapy
Engineered TCR Therapy
Vaccines
Targeted Therapy
Chapter 10 Regulatory Landscape and Pipeline Analysis
